Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) EBITDA Margin (2016 - 2025)

Regen BioPharma (RGBP) has disclosed EBITDA Margin for 11 consecutive years, with 207.28% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin fell 6343.0% to 207.28% in Q3 2025 year-over-year; TTM through Sep 2025 was 143.11%, a 5639.0% increase, with the full-year FY2025 number at 143.11%, up 3326.0% from a year prior.
  • EBITDA Margin was 207.28% for Q3 2025 at Regen BioPharma, down from 69.01% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 6.98% in Q3 2021 to a low of 1466.08% in Q4 2022.
  • A 5-year average of 221.98% and a median of 145.49% in 2021 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -112973bps in 2022, then soared 125820bps in 2023.
  • Regen BioPharma's EBITDA Margin stood at 336.35% in 2021, then plummeted by -336bps to 1466.08% in 2022, then soared by 86bps to 207.88% in 2023, then surged by 50bps to 103.92% in 2024, then tumbled by -99bps to 207.28% in 2025.
  • Per Business Quant, the three most recent readings for RGBP's EBITDA Margin are 207.28% (Q3 2025), 69.01% (Q2 2025), and 191.91% (Q1 2025).